Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 140

1.

Multiple sclerosis as differential diagnosis of radionecrosis for post-irradiation brain lesions: A case report.

Guillemin F, Biau J, Conde S, Clavelou P, Dupic G.

Clin Transl Radiat Oncol. 2020 Jan 9;21:44-48. doi: 10.1016/j.ctro.2020.01.001. eCollection 2020 Mar.

2.

Expert opinion: Criteria for second-line treatment failure in patients with multiple sclerosis.

Vermersch P, De Sèze J, Clavelou P, Durand-Dubief F, Maillart E, Mekies C, Moreau T, Papeix C, Tourbah A, Labauge P.

Mult Scler Relat Disord. 2019 Nov;36:101406. doi: 10.1016/j.msard.2019.101406. Epub 2019 Sep 19.

PMID:
31563076
3.

Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals.

Schwab N, Schneider-Hohendorf T, Pignolet B, Bucciarelli F, Scandella L, Ciron J, Biotti D, Lebrun-Frenay C, Mathey G, Clavelou P, Pelletier J, Ostkamp P, Meinl I, Windhagen S, Klotz L, Gross CC, Meuth SG, Deisenhammer F, Brassat D, Wiendl H; Best-MS Study Group.

Neurology. 2019 Sep 17;93(12):550-554. doi: 10.1212/WNL.0000000000008135. Epub 2019 Aug 22. No abstract available.

PMID:
31439633
4.

Whole-body reversible neuropathic pain associated with right parieto-temporal operculum single inflammatory lesion in a patient with multiple sclerosis: A case report.

Poncet-Megemont L, Dallel R, Chassain C, Perrey A, Mathais S, Clavelou P, Moisset X.

Eur J Pain. 2019 Nov;23(10):1763-1766. doi: 10.1002/ejp.1464. Epub 2019 Aug 22.

PMID:
31376307
5.

Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis.

Laplaud DA, Casey R, Barbin L, Debouverie M, De Sèze J, Brassat D, Wiertlewski S, Brochet B, Pelletier J, Vermersch P, Edan G, Lebrun-Frenay C, Clavelou P, Thouvenot E, Camdessanché JP, Tourbah A, Stankoff B, Al Khedr A, Cabre P, Lubetzki C, Papeix C, Berger E, Heinzlef O, Debroucker T, Moreau T, Gout O, Bourre B, Wahab A, Labauge P, Magy L, Defer G, Guennoc AM, Maubeuge N, Labeyrie C, Patry I, Nifle C, Casez O, Michel L, Rollot F, Leray E, Vukusic S, Foucher Y; SFSEP and OFSEP groups.

Neurology. 2019 Aug 13;93(7):e635-e646. doi: 10.1212/WNL.0000000000007938. Epub 2019 Jul 12.

6.

Foot Function Index: A Promising Questionnaire for Individuals With Charcot-Marie-Tooth Disease Type 1A.

Bihel L, Reynaud V, Givron P, Clavelou P, Cornut-Chauvinc C, Pereira B, Thomas E, Taithe F, Coudeyre E.

Arch Phys Med Rehabil. 2019 Dec;100(12):2403-2406. doi: 10.1016/j.apmr.2019.06.003. Epub 2019 Jun 28.

PMID:
31255638
7.

Specific lumbar puncture training during clinical clerkship durably increases atraumatic needle use.

Moisset X, Pereira B, Jamet C, Saturnin A, Clavelou P.

PLoS One. 2019 Jun 10;14(6):e0218004. doi: 10.1371/journal.pone.0218004. eCollection 2019.

8.

Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS.

Lavie C, Rollot F, Durand-Dubief F, Marignier R, Ionescu I, Casey R, Moreau T, Tourniaire P, Hutchinson M, D'Hooghe MB, Laplaud DA, Clavelou P, De Sèze J, Debouverie M, Brassat D, Pelletier J, Lebrun-Frenay C, Le Page E, Castelnovo G, Berger E, Hautecoeur P, Heinzlef O, Durelli L, Clerico M, Trojano M, Patti F, Vukusic S; PRIMS and POPARTMUS investigators.

Mult Scler. 2019 Apr;25(4):591-600. doi: 10.1177/1352458518763080. Epub 2018 Mar 20.

PMID:
31081475
9.

First clinical inflammatory demyelinating events of the central nervous system in a population aged over 70 years: A multicentre study.

Lavandier N, Bonnan M, Carra-Dallière C, Charif M, Labauge P, Camdessanche JP, Edan G, Naudin A, Brassat D, Ciron J, Clavelou P, Dulau C, Moroso A, Brochet B, Ouallet JC; on behalf Société Francophone de la Sclérose en Plaques (SFSEP).

Mult Scler Relat Disord. 2019 Feb;28:309-312. doi: 10.1016/j.msard.2018.12.016. Epub 2018 Dec 14.

PMID:
30665072
10.

Walking Speed Is Correlated With the Isokinetic Muscular Strength of the Knee in Patients With Charcot-Marie-Tooth Type 1A.

Reynaud V, Morel C, Givron P, Clavelou P, Cornut-Chauvinc C, Pereira B, Taithe F, Coudeyre E.

Am J Phys Med Rehabil. 2019 May;98(5):422-425. doi: 10.1097/PHM.0000000000001084.

PMID:
30365400
11.

Dimethyl fumarate and teriflunomide for multiple sclerosis in a real-life setting: a French retrospective cohort study.

Condé S, Moisset X, Pereira B, Zuel M, Colamarino R, Maillet-Vioud M, Lauxerois M, Taithe F, Clavelou P; Réseau NeuroSEP Auvergne.

Eur J Neurol. 2019 Mar;26(3):460-467. doi: 10.1111/ene.13839. Epub 2018 Nov 9.

PMID:
30320947
12.

Treatment satisfaction and quality of life in patients treated with fingolimod.

Mékiès C, Heinzlef O, Jenny B, Ramelli AL, Clavelou P.

Patient Prefer Adherence. 2018 May 22;12:899-907. doi: 10.2147/PPA.S144021. eCollection 2018.

13.

MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study.

Tourbah A, Gout O, Vighetto A, Deburghgraeve V, Pelletier J, Papeix C, Lebrun-Frenay C, Labauge P, Brassat D, Toosy A, Laplaud DA, Outteryck O, Moreau T, Debouverie M, Clavelou P, Heinzlef O, De Sèze J, Defer G, Sedel F, Arndt C.

CNS Drugs. 2018 Jul;32(7):661-672. doi: 10.1007/s40263-018-0528-2.

14.

Decreased prevalence of cancer in patients with multiple sclerosis: A case-control study.

Moisset X, Perié M, Pereira B, Dumont E, Lebrun-Frenay C, Lesage FX, Dutheil F, Taithe F, Clavelou P.

PLoS One. 2017 Nov 27;12(11):e0188120. doi: 10.1371/journal.pone.0188120. eCollection 2017.

15.

Cognition and quality of life in clinically isolated syndrome patients starting a disease modifying therapy in the QUALICIS study may not predict treatment response at one year.

Cohen M, Brochet B, Clavelou P, Le Page E, Vermersch P, Tourbah A, Moreau T, Joly H, Sakarovitch C, Lebrun C; Qualicis Study Group.

J Neurol Sci. 2017 Nov 15;382:73-78. doi: 10.1016/j.jns.2017.09.030. Epub 2017 Sep 22.

PMID:
29111024
16.

Improvement of quality of life and its relationship with neuropsychiatric outcomes in patients with multiple sclerosis starting treatment with natalizumab: A 3-year follow-up multicentric study.

Planche V, Moisset X, Morello R, Dumont E, Gibelin M, Charré-Morin J, Saubusse A, Mondou A, Reuter F, Defer G, Pelletier J, Brochet B, Clavelou P.

J Neurol Sci. 2017 Nov 15;382:148-154. doi: 10.1016/j.jns.2017.10.008. Epub 2017 Oct 6.

PMID:
29111011
17.

Medication overuse reinstates conditioned pain modulation in women with migraine.

Guy N, Voisin D, Mulliez A, Clavelou P, Dallel R.

Cephalalgia. 2018 May;38(6):1148-1158. doi: 10.1177/0333102417727545. Epub 2017 Aug 20.

PMID:
28825315
18.

Exploring the diagnosis delay and ALS functional impairment at diagnosis as relevant criteria for clinical trial enrolment.

Hamidou B, Marin B, Lautrette G, Nicol M, Camu W, Corcia P, Arnes-Bes MC, Tranchant C, Clavelou P, Hannequin D, Maurice G, Beauvais K, Antoine JC, Danel-Brunaud V, Viader F, Preux PM, Couratier P.

Amyotroph Lateral Scler Frontotemporal Degener. 2017 Nov;18(7-8):519-527. doi: 10.1080/21678421.2017.1353098. Epub 2017 Aug 1.

PMID:
28762856
19.

Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy.

Fissolo N, Pignolet B, Matute-Blanch C, Triviño JC, Miró B, Mota M, Perez-Hoyos S, Sanchez A, Vermersch P, Ruet A, de Sèze J, Labauge P, Vukusic S, Papeix C, Almoyna L, Tourbah A, Clavelou P, Moreau T, Pelletier J, Lebrun-Frenay C, Montalban X, Brassat D, Comabella M; Biomarkers and Response to Natalizumab for Multiple Sclerosis Treatment (BIONAT), Best EScalation Treatment in Multiple Sclerosis (BEST-MS), and the Société Francophone de la Sclérose En Plaques (SFSEP) Network.

Ann Neurol. 2017 Aug;82(2):186-195. doi: 10.1002/ana.24987. Epub 2017 Jul 22.

PMID:
28681388
20.

Ketamine Infusion Combined With Magnesium as a Therapy for Intractable Chronic Cluster Headache: Report of Two Cases.

Moisset X, Clavelou P, Lauxerois M, Dallel R, Picard P.

Headache. 2017 Sep;57(8):1261-1264. doi: 10.1111/head.13135. Epub 2017 Jul 3.

PMID:
28670718
21.

Natalizumab-PML survivors with subsequent MS treatment: Clinico-radiologic outcome.

Maillart E, Vidal JS, Brassat D, Stankoff B, Fromont A, de Sèze J, Taithe F, Clavelou P, Bourre B, Delvaux V, Rico A, Labauge P, Tourbah A, Lebrun C, Pelletier J, Moreau T, Louapre C, Lubetzki C, Papeix C.

Neurol Neuroimmunol Neuroinflamm. 2017 Apr 14;4(3):e346. doi: 10.1212/NXI.0000000000000346. eCollection 2017 May.

22.

Migraine prevalence in inflammatory bowel disease patients: A tertiary-care centre cross-sectional study.

Moisset X, Bommelaer G, Boube M, Ouchchane L, Goutte M, Dapoigny M, Dallel R, Guttmann A, Clavelou P, Buisson A.

Eur J Pain. 2017 Oct;21(9):1550-1560. doi: 10.1002/ejp.1056. Epub 2017 May 16.

PMID:
28508514
23.

Hereditary neuropathy with liability to pressure palsy in patients under 30 years old: Neurophysiological data and proposed electrodiagnostic criteria.

Robert-Varvat F, Jousserand G, Bouhour F, Vial C, Cintas P, Echaniz-Laguna A, Delmont E, Clavelou P, Chauplannaz G, Jomir L, Pereon Y, Leonard-Louis S, Manel V, Antoine JC, Lacour A, Camdessanche JP.

Muscle Nerve. 2018 Feb;57(2):217-221. doi: 10.1002/mus.25666. Epub 2017 Jun 11.

PMID:
28407266
24.

Liver X Receptor Genes Variants Modulate ALS Phenotype.

Mouzat K, Molinari N, Kantar J, Polge A, Corcia P, Couratier P, Clavelou P, Juntas-Morales R, Pageot N, Lobaccaro J-A, Raoul C, Lumbroso S, Camu W.

Mol Neurobiol. 2018 Mar;55(3):1959-1965. doi: 10.1007/s12035-017-0453-2. Epub 2017 Feb 27.

PMID:
28244008
25.

Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis.

Brochet B, Deloire MS, Perez P, Loock T, Baschet L, Debouverie M, Pittion S, Ouallet JC, Clavelou P, de Sèze J, Collongues N, Vermersch P, Zéphir H, Castelnovo G, Labauge P, Lebrun C, Cohen M, Ruet A; PROMESS study investigators.

PLoS One. 2017 Jan 3;12(1):e0168834. doi: 10.1371/journal.pone.0168834. eCollection 2017.

26.

Geographical Heterogeneity of Multiple Sclerosis Prevalence in France.

Pivot D, Debouverie M, Grzebyk M, Brassat D, Clanet M, Clavelou P, Confavreux C, Edan G, Leray E, Moreau T, Vukusic S, Hédelin G, Guillemin F.

PLoS One. 2016 Dec 9;11(12):e0167556. doi: 10.1371/journal.pone.0167556. eCollection 2016.

27.

CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy.

Pignolet B, Schwab N, Schneider-Hohendorf T, Bucciarelli F, Biotti D, Averseng-Peaureaux D, Outteryck O, Ongagna JC, de Sèze J, Brochet B, Ouallet JC, Debouverie M, Pittion S, Defer G, Derache N, Hautecoeur P, Tourbah A, Labauge P, Castelnovo G, Clavelou P, Berger E, Pelletier J, Rico A, Zéphir H, Laplaud D, Wiertlewski S, Camu W, Thouvenot E, Casez O, Moreau T, Fromont A, Vukusic S, Papeix C, Vermersch P, Comabella M, Lebrun-Frenay C, Wiendl H, Brassat D; BIONAT, SFSEP, and BEST-MS networks.

Neurology. 2016 Dec 6;87(23):2491-2494. Epub 2016 Nov 4. No abstract available.

PMID:
27815407
28.

Fixed 50:50 mixture of nitrous oxide and oxygen to reduce lumbar-puncture-induced pain: a randomized controlled trial.

Moisset X, Sia MA, Pereira B, Taithe F, Dumont E, Bernard L, Clavelou P.

Eur J Neurol. 2017 Jan;24(1):46-52. doi: 10.1111/ene.13127. Epub 2016 Sep 25.

PMID:
27666149
29.

MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study.

Tourbah A, Lebrun-Frenay C, Edan G, Clanet M, Papeix C, Vukusic S, De Sèze J, Debouverie M, Gout O, Clavelou P, Defer G, Laplaud DA, Moreau T, Labauge P, Brochet B, Sedel F, Pelletier J; MS-SPI study group.

Mult Scler. 2016 Nov;22(13):1719-1731. Epub 2016 Sep 1.

30.

Who Performs Lumbar Puncture, How Many Do They Perform, How and Why? A Retrospective Study of 6,594 Cases.

Moisset X, Ruet A, Brochet B, Planche V, Jaffeux P, Gilleron V, Ong N, Clavelou P.

Eur Neurol. 2016;76(1-2):8-11. doi: 10.1159/000447452. Epub 2016 Jun 24.

PMID:
27336667
31.

Evaluation of quality of life and fatigue in radiologically isolated syndrome.

Lebrun C, Cohen M, Clavelou P; SFSEP.

Rev Neurol (Paris). 2016 Jun-Jul;172(6-7):392-5. doi: 10.1016/j.neurol.2016.04.004. Epub 2016 May 2.

PMID:
27158044
32.

Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study.

Peyro Saint Paul L, Creveuil C, Heinzlef O, De Seze J, Vermersch P, Castelnovo G, Cabre P, Debouverie M, Brochet B, Dupuy B, Lebiez P, Sartori É, Clavelou P, Brassat D, Lebrun-Frenay C, Daplaud D, Pelletier J, Coman I, Hautecoeur P, Tourbah A, Defer G.

J Neurol Sci. 2016 Apr 15;363:69-76. doi: 10.1016/j.jns.2016.02.012. Epub 2016 Feb 6.

PMID:
27000224
33.

[Scientific communications at the 20th "Journées de neurologie de langue française"].

Clavelou P.

Rev Neurol (Paris). 2016 Apr;172 Suppl 1:A1. doi: 10.1016/j.neurol.2016.03.001. French. No abstract available.

PMID:
26997504
34.

Anti-NMDA-R encephalitis: Should we consider extreme delta brush as electrical status epilepticus?

Chanson E, Bicilli É, Lauxerois M, Kauffmann S, Chabanne R, Ducray F, Honnorat J, Clavelou P, Rosenberg S.

Neurophysiol Clin. 2016 Feb;46(1):17-25. doi: 10.1016/j.neucli.2015.12.009. Epub 2016 Feb 26.

PMID:
26922283
35.

Evaluation of the application of the European guidelines for the diagnosis and clinical care of amyotrophic lateral sclerosis (ALS) patients in six French ALS centres.

Marin B, Beghi E, Vial C, Bernard E, Lautrette G, Clavelou P, Guy N, Lemasson G, Debruxelles S, Cintas P, Antoine JC, Camdessanche JP, Logroscino G, Preux PM, Couratier P; EURECALS consortium.

Eur J Neurol. 2016 Apr;23(4):787-95. doi: 10.1111/ene.12941. Epub 2016 Feb 1.

PMID:
26833536
36.

Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study.

Barbin L, Rousseau C, Jousset N, Casey R, Debouverie M, Vukusic S, De Sèze J, Brassat D, Wiertlewski S, Brochet B, Pelletier J, Vermersch P, Edan G, Lebrun-Frenay C, Clavelou P, Thouvenot E, Camdessanché JP, Tourbah A, Stankoff B, Al Khedr A, Cabre P, Papeix C, Berger E, Heinzlef O, Debroucker T, Moreau T, Gout O, Bourre B, Créange A, Labauge P, Magy L, Defer G, Foucher Y, Laplaud DA; CFSEP and OFSEP groups.

Neurology. 2016 Feb 23;86(8):771-8. doi: 10.1212/WNL.0000000000002395. Epub 2016 Jan 29.

37.

Seronegative Lyme neuroborreliosis in a patient treated by rituximab.

Gampourou F, Taithe F, Moisset X, Clavelou P.

Rev Neurol (Paris). 2016 Feb;172(2):166-7. doi: 10.1016/j.neurol.2015.06.009. Epub 2015 Aug 28. No abstract available.

PMID:
26318890
38.

Is there pain with neuropathic characteristics in patients with amyotrophic lateral sclerosis? A cross-sectional study.

Moisset X, Cornut-Chauvinc C, Clavelou P, Pereira B, Dallel R, Guy N.

Palliat Med. 2016 May;30(5):486-94. doi: 10.1177/0269216315600332. Epub 2015 Aug 12.

PMID:
26269326
39.

Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability.

Zéphir H, Bernard-Valnet R, Lebrun C, Outteryck O, Audoin B, Bourre B, Pittion S, Wiertlewski S, Ouallet JC, Neau JP, Ciron J, Clavelou P, Marignier R, Brassat D.

J Neurol. 2015 Oct;262(10):2329-35. doi: 10.1007/s00415-015-7852-y. Epub 2015 Jul 21.

PMID:
26194198
40.

Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study.

Leray E, Vukusic S, Debouverie M, Clanet M, Brochet B, de Sèze J, Zéphir H, Defer G, Lebrun-Frenay C, Moreau T, Clavelou P, Pelletier J, Berger E, Cabre P, Camdessanché JP, Kalson-Ray S, Confavreux C, Edan G.

PLoS One. 2015 Jul 6;10(7):e0132033. doi: 10.1371/journal.pone.0132033. eCollection 2015.

41.

Cognitive impairment in a population-based study of patients with multiple sclerosis: differences between late relapsing-remitting, secondary progressive and primary progressive multiple sclerosis.

Planche V, Gibelin M, Cregut D, Pereira B, Clavelou P.

Eur J Neurol. 2016 Feb;23(2):282-9. doi: 10.1111/ene.12715. Epub 2015 Apr 22.

PMID:
25903918
42.

A novel autosomal dominant leukodystrophy with specific MRI pattern.

Corlobé A, Taithe F, Clavelou P, Pierre E, Carra-Dallière C, Ayrignac X, Mouzat K, Lumbroso S, Menjot de Champfleur N, Koenig M, Boespflug-Tanguy O, Labauge P.

J Neurol. 2015;262(4):988-91. doi: 10.1007/s00415-015-7660-4. Epub 2015 Feb 17.

PMID:
25683759
43.

Adult-onset genetic leukoencephalopathies: a MRI pattern-based approach in a comprehensive study of 154 patients.

Ayrignac X, Carra-Dalliere C, Menjot de Champfleur N, Denier C, Aubourg P, Bellesme C, Castelnovo G, Pelletier J, Audoin B, Kaphan E, de Seze J, Collongues N, Blanc F, Chanson JB, Magnin E, Berger E, Vukusic S, Durand-Dubief F, Camdessanche JP, Cohen M, Lebrun-Frenay C, Brassat D, Clanet M, Vermersch P, Zephir H, Outteryck O, Wiertlewski S, Laplaud DA, Ouallet JC, Brochet B, Goizet C, Debouverie M, Pittion S, Edan G, Deburghgraeve V, Le Page E, Verny C, Amati-Bonneau P, Bonneau D, Hannequin D, Guyant-Maréchal L, Derache N, Defer GL, Moreau T, Giroud M, Guennoc AM, Clavelou P, Taithe F, Mathis S, Neau JP, Magy L, Devoize JL, Bataillard M, Masliah-Planchon J, Dorboz I, Tournier-Lasserve E, Levade T, Boespflug Tanguy O, Labauge P.

Brain. 2015 Feb;138(Pt 2):284-92. doi: 10.1093/brain/awu353. Epub 2014 Dec 19.

PMID:
25527826
44.

Prolonged continuous theta-burst stimulation is more analgesic than 'classical' high frequency repetitive transcranial magnetic stimulation.

Moisset X, Goudeau S, Poindessous-Jazat F, Baudic S, Clavelou P, Bouhassira D.

Brain Stimul. 2015 Jan-Feb;8(1):135-41. doi: 10.1016/j.brs.2014.10.006. Epub 2014 Oct 18.

PMID:
25456979
45.

Adult-onset autosomal dominant centronuclear myopathy due to BIN1 mutations.

Böhm J, Biancalana V, Malfatti E, Dondaine N, Koch C, Vasli N, Kress W, Strittmatter M, Taratuto AL, Gonorazky H, Laforêt P, Maisonobe T, Olivé M, Gonzalez-Mera L, Fardeau M, Carrière N, Clavelou P, Eymard B, Bitoun M, Rendu J, Fauré J, Weis J, Mandel JL, Romero NB, Laporte J.

Brain. 2014 Dec;137(Pt 12):3160-70. doi: 10.1093/brain/awu272. Epub 2014 Sep 25.

PMID:
25260562
46.

Soluble IL-2 receptor: a biomarker for assessing myositis activity.

Tournadre A, Dubost JJ, Soubrier M, Ruivard M, Souteyrand P, Schmidt J, Clavelou P, Tridon A, Ristori JM.

Dis Markers. 2014;2014:472624. doi: 10.1155/2014/472624. Epub 2014 Feb 4.

47.

Two cases of bilateral amiodarone-associated optic neuropathy.

Chassang B, Bonnin N, Moisset X, Citron B, Clavelou P, Chiambaretta F.

J Fr Ophtalmol. 2014 Mar;37(3):231-6. doi: 10.1016/j.jfo.2013.12.004. Epub 2014 Feb 24.

PMID:
24576569
48.

Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study.

Cohen M, Maillart E, Tourbah A, De Sèze J, Vukusic S, Brassat D, Anne O, Wiertlewski S, Camu W, Courtois S, Ruet A, Debouverie M, Le Page E, Casez O, Heinzlef O, Stankoff B, Bourre B, Castelnovo G, Rico A, Berger E, Camdessanche JP, Defer G, Clavelou P, Al Khedr A, Zephir H, Fromont A, Papeix C, Brochet B, Pelletier J, Lebrun C; Club Francophone de la Sclérose en Plaques Investigators.

JAMA Neurol. 2014 Apr;71(4):436-41. doi: 10.1001/jamaneurol.2013.6240.

PMID:
24566807
49.

Can we optimize our teams? Multidisciplinary care for multiple sclerosis.

Clavelou P.

Expert Rev Neurother. 2013 Dec;13(12 Suppl):39-44. doi: 10.1586/14737175.2013.865873. Review.

PMID:
24289841
50.

Migraine headaches and pain with neuropathic characteristics: comorbid conditions in patients with multiple sclerosis.

Moisset X, Ouchchane L, Guy N, Bayle DJ, Dallel R, Clavelou P.

Pain. 2013 Dec;154(12):2691-9. doi: 10.1016/j.pain.2013.07.050. Epub 2013 Aug 2.

Supplemental Content

Loading ...
Support Center